InvestSMART

Immuron Limited (ASX:IMC)

ALERT: Price-sensitive ASX Announcement for IMC
Current share price for IMC : $0.034 -0.035 (-50.72%)+
Announcement
Release
29 Aug 2025 9:35AM
Price at Release
$0.069
Full Release
download
Summary
Immuron Limited's Appendix 4E Preliminary Final Report for the year ended 30 June 2025 details a comprehensive loss after income tax of $5,253,209, which is a decrease from the previous year's loss of $6,936,957. The company's total revenue from contracts with customers increased significantly to $7,287,002 from $4,902,865, driven by sales of hyperimmune products like Travelan across Australia, the United States, and Canada. Despite these gains, the cost of goods sold also rose substantially. Immuron's financial position at the end of the year shows net assets of $8,031,833, down from $12,709,444 in 2024, with a notable decrease in cash and cash equivalents. The company raised additional funds through share issues, with a net increase in share capital to $88,872,756. The report also highlights transactions involving share-based payments, including options and performance rights issued to key personnel. Notably, post-year-end events include a capital raising effort through an At The Market facility.
Key Points
  • Comprehensive loss after tax of $5,253,209 for the year ended 30 June 2025.
  • Revenue from contracts with customers increased to $7,287,002.
  • Net assets decreased to $8,031,833 from $12,709,444 in the previous year.
  • Significant decrease in cash and cash equivalents to $2,830,526.
  • Share capital increased to $88,872,756 due to share issues.
  • Continued issuance of options and performance rights to key personnel.
  • Post-year-end capital raising through At The Market facility in July 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.